



PRESS RELEASE April 17, 2007

Biovitrum's Annual Report and Business Review for 2006

Biovitrum AB (publ) announced today that the company's complete Annual Report for 2006 is now available as a PDF document for downloading or reading at www.biovitrum.com. A Business Review with condensed accounting data is also available as a PDF document. A printed version of the Business Review will be distributed to the share holders in the next few days.

Biovitrum's Annual General Meeting will be held May 3, 2007.

For additional information, please contact:

Biovitrum AB (publ)

Anders Martin-Löf, Director Investor Relations

Phone: +46 8 697 37 07, cell phone: +46 70 624 32 56

anders.martin-lof@biovitrum.com

Anna Karin Källén, Vice President, Corporate Communications

Phone: +46 8 697 20 85, cell phone: +46 73 433 20 85

annakarinn.kallen@biovitrum.com

About Biovitrum

Biovitrum is one of the largest biopharma companies in Europe. With operations in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals for unmet medical needs both for common diseases and conditions that affect smaller patient populations. Biovitrum has a broad and balanced R&D portfolio with several projects in clinical and preclinical phases for the treatment of obesity, diabetes, inflammation and eye and blood diseases as well as a number of well defined niche indications. Biovitrum develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. Biovitrum has revenues of approximately SEK 1.2 billion and 550 employees. Biovitrum is listed on the Stockholm Stock Exchange since September 15, 2006. For more information see www.biovitrum.com.